Biosplice Therapeutics

Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Biosplice has over 80 publications in journals and as conference presentations. The company is headquartered in San Diego, California.

The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug.